Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome.
Vanhauwaert R, Oury J, Vankerckhoven B, Steyaert C, Jensen SM, Vergoossen DLE, Kneip C, Santana L, Lim JL, Plomp JJ, Augustinus R, Koide S, Blanchetot C, Ulrichts P, Huijbers MG, Silence K, Burden SJ. Vanhauwaert R, et al. Among authors: blanchetot c. Sci Transl Med. 2024 Sep 18;16(765):eado7189. doi: 10.1126/scitranslmed.ado7189. Epub 2024 Sep 18. Sci Transl Med. 2024. PMID: 39292800
Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.
Budding K, Johansen LE, Van de Walle I, Dijkxhoorn K, de Zeeuw E, Bloemenkamp LM, Bos JW, Jansen MD, Curial CAD, Silence K, de Haard H, Blanchetot C, Van de Ven L, Leusen JHW, Pasterkamp RJ, van den Berg LH, Hack CE, Boross P, van der Pol WL. Budding K, et al. Among authors: blanchetot c. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1):e1107. doi: 10.1212/NXI.0000000000001107. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34759020 Free PMC article.
ARGX-117, a therapeutic complement inhibiting antibody targeting C2.
Van de Walle I, Silence K, Budding K, Van de Ven L, Dijkxhoorn K, de Zeeuw E, Yildiz C, Gabriels S, Percier JM, Wildemann J, Meeldijk J, Simons PJ, Boon L, Cox L, Holgate R, Urbanus R, Otten HG, Leusen JHW, Blanchetot C, de Haard H, Hack CE, Boross P. Van de Walle I, et al. Among authors: blanchetot c. J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7. doi: 10.1016/j.jaci.2020.08.028. Epub 2020 Sep 11. J Allergy Clin Immunol. 2021. PMID: 32926878 Free PMC article.
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P. Hultberg A, et al. Among authors: blanchetot c. Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3. Cancer Res. 2015. PMID: 26141862 Free article.
VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy.
Bosco J, Zhou Z, Gabriëls S, Verma M, Liu N, Miller BK, Gu S, Lundberg DM, Huang Y, Brown E, Josiah S, Meiyappan M, Traylor MJ, Chen N, Asakura A, De Jonge N, Blanchetot C, de Haard H, Duffy HS, Keefe D. Bosco J, et al. Among authors: blanchetot c. Mol Ther Methods Clin Dev. 2021 Mar 23;21:369-381. doi: 10.1016/j.omtm.2021.03.013. eCollection 2021 Jun 11. Mol Ther Methods Clin Dev. 2021. PMID: 33898634 Free PMC article.
A bispecific antibody strategy to target multiple type 2 cytokines in asthma.
Godar M, Deswarte K, Vergote K, Saunders M, de Haard H, Hammad H, Blanchetot C, Lambrecht BN. Godar M, et al. Among authors: blanchetot c. J Allergy Clin Immunol. 2018 Oct;142(4):1185-1193.e4. doi: 10.1016/j.jaci.2018.06.002. Epub 2018 Jun 8. J Allergy Clin Immunol. 2018. PMID: 29890236 Free PMC article.
44 results